A new treatment for chagas disease has been found to be safer and more practical with once-daily dosing, reducing side effects by nearly 40% and improving treatment adherence. The 30-day benznidazole regimen is as effective as the standard 60-day treatment and has the potential to increase treatment completion rates.
A 30-day course of benznidazole taken once a day has been shown to significantly reduce side effects and improve treatment adherence for people with chronic chagas disease. The treatment, which is less toxic and easier to follow than the current standard regimen, was found to be non-inferior to the 60-day standard regimen.
Researchers discovered that Trypanosoma cruzi, the Chagas disease parasite, alters its RNA to adapt to infect mammals, a process that could lead to new treatments. The study found that modifications in transfer RNA facilitate protein production, influencing the parasite's transformation from a non-infective to an infectious phase.
A computational protocol has been established by University of Kent researchers to accurately identify reactions that can result in successful drug candidates for Chagas disease. This approach reduces the need for trial-and-error, prioritizing promising compounds earlier and making the drug discovery process faster and more affordable.
The inaugural US-based Chagas disease conference will strengthen research and patient care efforts in the US, building on recognition of the disease as a national concern. Approximately 300,000 Americans are infected with Chagas disease, and improved surveillance, testing, and research can help address severe heart complications.
A UTEP study has discovered a significant increase in parasitic infection rates among kissing bugs in the Borderlands, raising concerns about local transmission of Chagas disease. The research suggests that the disease is becoming an increasingly public health issue for the Southwest, affecting approximately 6 million people worldwide.
A simple echocardiography method analyzes myocardial deformation to predict cardiac complications in chronic Chagas disease. The study found that patients with a greater GLS value had a higher risk of death and complications.
A new study found that over 30% of kissing bugs in Florida harbor the parasite Trypanosoma cruzi, which causes Chagas disease. The researchers suggest preventative measures such as inspecting homes for entry points and removing wood piles to safeguard against transmission.
Researchers at Texas A&M University and the University of Georgia are working on interventions to impact both canine and human health. The study combines field and laboratory research, treating dogs, measuring clinical outcomes, and studying ecological factors to advance Chagas disease research.
Researchers at Auburn University and FIOCRUZ have made significant strides in understanding Chagas Disease mechanisms through novel molecular dynamics simulation. The study identifies new potential targets for therapeutic intervention, which could lead to the development of drugs to block the infection process.
UTEP researchers have developed a new diagnostic method that significantly enhances the sensitivity of parasite detection in blood samples, making it a more reliable indicator of parasites in the blood. The method uses magnetic beads to extract parasitic DNA from blood samples, outperforming traditional silica columns.
A landmark study led by ISGlobal found that combining rapid diagnostic tests with conventional serology improves access to diagnosis for Chagas disease. The prevalence of Chagas is six times higher in an indigenous community in Paraguay compared to the capital.
Switzerland is affected by Chagas disease, a tropical disease that can cause severe cardiac and digestive complications if left untreated. The Swiss government has established the Swiss Chagas Network to address this issue through coordinated measures.
A novel diagnostic test combining LAMP molecular amplification with a 3D printer-based DNA extraction system shows comparable sensitivity to PCR, offering a simple and rapid solution for detecting T. cruzi infection in newborns. Early detection is crucial for effective treatment, which was successfully applied in the study.
Chronic Chagas Disease can cause irreversible heart damage due to the destruction of adipose tissue by Trypanosoma cruzi, releasing particles that induce dysfunction. The study reveals that adipome release regulates immunometabolic signaling and promotes inflammation in cardiac remodeling.
Researchers used CRISPR-Cas9 to genetically modify kissing bugs, opening a door to controlling Chagas disease. The new method, ReMOT Control, allows efficient and targeted editing of genes in eggs.
The article discusses the high prevalence of Trypanosoma cruzi in naturally infected dogs and monkeys in the US, which can inform human infection detection and treatment strategies. This abundance provides a unique opportunity to advance solutions for Chagas disease, as information from other species can directly inform researchers on ...
Researchers found that infected individuals with multiple strains of the T. cruzi parasite were better able to control the disease, while those with a progressive form had fewer strains. This discovery provides a new framework for developing more effective treatments and vaccines.
UC researchers investigate signaling pathway of Trypanosoma cruzi to transform and reproduce, aiming to find better drug targets to kill the parasite. The study reveals crucial proteins involved in the parasite's survival and transmission, highlighting potential strategies for disease control.
A recent study found nearly 2,800 Latin Americans were infected with the parasite causing Chagas disease upon arrival in Barcelona. The majority had heart lesions, emphasizing the need for screening and prevention programs.
A 16-year analysis of Brazilian research funding reveals stagnant funding for neglected tropical diseases, including chikungunya, Chagas disease, schistosomiasis, and malaria. Systematic underfunding is observed even among these diseases, which are considered neglected tropical diseases.
Researchers identified a genetic variant linked to digestive disturbances in patients with Chagas megaesophagus, a disorder characterized by esophageal dilation and loss of motility. The study suggests that increased interferon-gamma production leads to mitochondrial dysfunction, contributing to the development of the disease.
A new antiparasitic compound has shown 100% efficacy in eliminating T. cruzi, the parasite that causes Chagas disease, in mice and non-human primates. The treatment could provide a safer alternative to current medications with significant side effects and variable efficacy.
Chagas disease affects 8 million people in the US and Latin America, causing significant healthcare costs and economic impact. Researchers are investigating a potential treatment using the carnitine molecule, which may help compensate for negative effects of infections and reduce drug resistance.
A nationwide survey in El Salvador identified areas with high Chagas disease transmission, highlighting the need for targeted vector control measures. The study suggests that continued efforts are necessary to combat this neglected tropical disease.
Despite advances in biology and medicinal chemistry, research on schistosomiasis and other parasitic worm diseases remains at an early stage. Novel molecular targets and parasite signaling pathways may contribute to the development of new treatments.
The São Paulo School of Advanced Science on Pathogenic Trypanosomatids will bring together experts from different fields to discuss the fight against leishmaniasis and Chagas disease. Researchers will share state-of-the-art science and results of new research on epigenetics, drug discovery, and molecular biology.
Researchers at Karolinska Institutet have mapped the formation of hybrid strains in Trypanosoma cruzi, a parasite causing chronic infection and severe symptoms. These hybrids are more effective at evading the immune system and causing disease, but understanding their formation can help develop new diagnostic and treatment methods.
Researchers found that Chagas trypanosomes change the bacterial community in predatory bugs' intestines, leading to a decrease in diversity and an increase in certain pathogenic bacteria. The study also identified four bacteria species crucial for bug survival, which could be used to develop defensive substances against the parasite.
Researchers have discovered that scorpion venom molecule VmCT1 is effective against all three stages of the parasite that causes Chagas disease. Novel analogs with arginine substitutions displayed enhanced biological activity and better selectivity, offering new prospects for treatment.
The metabolic state of a disease-causing parasite influences its resistance to current drugs, according to a new study published in eLife. The research found that the sensitivity of amastigotes to azole drugs increases significantly in the presence of certain concentrations of glutamine.
A new study examines local attitudes towards Chagas disease and its transmission, highlighting the need for culturally sensitive campaigns. The findings suggest that social and cultural factors play a significant role in shaping public perception, particularly regarding preventive measures and treatment options.
A more intensive treatment schedule with currently available therapeutics has been shown to completely clear the infection in infected mice. Researchers used light sheet fluorescence microscopy to view intact whole organs from infected mice and found that a less frequent dosage of benznidazole could be effective.
A new study from the University of Colorado School of Medicine reveals that asymptomatic Chagas patients are at a high risk of developing cardiomyopathy, a progressive heart disease. The risk more than doubles among patients with acute infections, according to the study published in JAMA Network Open.
Researchers have synthesized novel lipophilic guanylhydrazones, finding that adamantane derivatives with hydrophobic bulky substituents exhibit synergistic trypanocidal activity. The most potent compound, G8, demonstrates nanomolar efficacy against T. brucei.
Combining two rapid diagnostic tests effectively diagnoses chronic Chagas disease in the field, showing a sensitivity of 97% and specificity of 96.1%. High prevalence of infection was also observed in the region, highlighting the potential for these tests to detect infected individuals.
Researchers report that two commercially-available rapid diagnostic tests can be combined for conclusive diagnosis of Chagas disease. The tests provided a sensitivity of 97.7% and specificity of 96.1%, outperforming the conventional serological method.
A Brazilian consortium is working with international partners to develop new treatments for Malaria, Chagas disease and visceral leishmaniasis. The goal is to create a rapid-acting anti-malarial molecule that can eliminate the parasite without resistance development.
Memantine, a drug used to treat Alzheimer's disease, has been shown to reduce parasite levels by 40% and increase survival rates of mice with Chagas disease. The treatment also lowered parasite levels in the hearts of infected animals, providing a promising alternative therapy for this neglected tropical disease.
Scientists have discovered that the Trypanosoma cruzi parasite, responsible for Chagas disease, can reproduce sexually after analyzing its genomic code in unprecedented detail. The study reveals that some groups of parasites exhibit high levels of sexuality, while others remain abstinent.
University of Alberta researchers found a critical protein called PEX3 in the cells of a deadly infectious parasite, opening the door to less harmful treatment options for millions suffering from diseases. The discovery could lead to effective drug treatments that target and kill parasites without harming human hosts.
Researchers identified key genes involved in parasite adherence using a non-disease-causing species Crithidia fasciculata. The study found significant transcriptional differences between the swimming and adherent forms of the parasite.
A new AI-powered tool can identify triatomine bugs, also known as 'kissing bugs', that spread the incurable disease Chagas with high accuracy, allowing public health officials to target prevention efforts. The algorithm achieved 95.8% and 98.9% correct identification rates for Mexican and Brazilian species, respectively.
DNDi and Atomwise collaborate to develop first-in-class treatments for Chagas disease using AI, delivering drug-like compounds that will undergo further optimization and potential drug development. The research aims to address a public health challenge affecting millions worldwide.
Despite advancements in disease research, neglected tropical diseases and others continue to require attention, with only a small proportion of new drugs addressing these conditions. Novel treatments like bedaquiline and tafenoquine offer hope, but much work remains to be done.
A two-week treatment course showed similar efficacy and fewer side effects than the standard eight-week treatment in adult patients with chronic Chagas disease. The results bring new hope for people living with this silent disease and could change access to treatment in endemic countries.
A two-week treatment course for adult patients with chronic Chagas disease was shown to be as effective as an eight-week standard treatment in improving sustained parasitological response at six months. The new regimen also significantly reduced side effects, encouraging wider adoption by the medical community.
Experts warn of a surge in vector-borne diseases as Venezuela's humanitarian crisis worsens, with malaria cases increasing by 359% since 2010. The crisis is also leading to a resurgence of other diseases like Chagas disease and dengue, threatening public health gains in the country.
High research intensity relative to published global disease burden was found for influenza, HIV/AIDS, hepatitis C, and tuberculosis, while paratyphoid fever had low research intensity. Certain neglected tropical diseases such as Chagas disease, leishmaniasis, and leprosy also showed high research intensity.
Researchers found benznidazole improves clinical and parasitological outcomes in Chagas patients treated early, lowering mortality rates and parasite counts. This study provides evidence for using benznidazole to treat early-stage Chagas disease.
A new study reports that over 100 working dogs in the US have been infected with Chagas disease, a tropical parasite known to cause heart problems. The dogs were tested for antibodies to the parasite and many showed signs of heart abnormalities associated with the disease.
Researchers analyzed DNA from kissing bugs to understand the complex interactions between humans, parasites, and microbes involved in Chagas disease. The study found two strains of Trypanosome cruzi and a higher bacterial species richness in infected insects.
UTEP scientists have received a $6 million grant from the National Institutes of Health to develop new regimens and biomarkers for Chagas disease treatment. The researchers aim to improve the efficacy and safety of current treatments, which are toxic and have low effectiveness.
Chagas disease, caused by a parasite, has spread to the US and other countries, carrying a high risk of heart disease. Early detection is critical for treatment, which can be cured with medications having a 60-90% success rate.
FIND and DNDi partner to generate evidence for policy change and scale-up of HCV diagnosis and treatment in Malaysia. Decentralized screening using pre-qualified rapid diagnostic tests will be initiated, linking positive cases to direct-acting antiviral treatment.
Researchers found that PI3Kγ expression increases during T. cruzi infection, essential for avoiding excessive inflammation and controlling heart parasitemia. The enzyme's absence in macrophages impairs their ability to kill parasites and control inflammation.
Researchers successfully attached miniature radio transmitters to kissing bugs in Texas, tracking their movements and revealing average distance traveled of 12.5 feet. The study opens the door for more in-depth studies into kissing bugs' movements and potential impact on Chagas disease.
Two clinical trials evaluate the frequency and type of adverse reactions to benznidazole in chronically infected adults. The studies found that the majority of adverse reactions (90%) were mild and appeared within the first month of treatment.
A retrospective study found that 49% of Latin American migrants screened positive for Chagas disease, with a higher percentage of patients with strongyloidiasis infected by the parasite. The authors recommend implementing a combined screening program to address both infections.
A new case study reveals the potential for Chagas disease transmission among individuals with family ties to Central and South American nations. Early detection and treatment can prevent serious long-term effects such as heart failure.